Arshad Khanani, MD: 48-Week Results of BEHOLD Study on UXB1325 for DME
In: HCP Live (USA), 2023-07-31, S. 3
Zeitungsartikel
Zugriff:
New data indicates the potential proof-of-concept for the safety, tolerability, and efficacy of UBX1325 in patients with diabetic macular edema (DME), who have residual visual acuity deficits and macular edema after ?6 months of anti-vascular endothelial growth factor (VEGF) therapy. The research, presented at the American Society of Retina Specialists (ASRS) 41st Annual Meeting in a late-breaking session, suggests the novel senolytic BCL-xL inhibitor may represent a future treatment option for patients with DME...
Titel: |
Arshad Khanani, MD: 48-Week Results of BEHOLD Study on UXB1325 for DME
|
---|---|
Autor/in / Beteiligte Person: | Iapoce, Connor |
Zeitschrift: | HCP Live (USA), 2023-07-31, S. 3 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|